|
Market Closed -
Other stock markets
|
After hours 00:00:00 | |||
| 989.12 USD | +0.41% |
|
988.00 | -0.11% |
| 05:05am | Almirall Reports Positive Results for Late-stage Trial of Atopic Dermatitis Medication | MT |
| 03-16 | LyondellBasell Announces Management Changes | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 10.71 | 11 | 11.88 | 15.33 | 19.42 | |||||
Return on Total Capital | 20.66 | 20.03 | 20.91 | 25.29 | 31.07 | |||||
Return On Equity % | 74.52 | 62.67 | 48.43 | 84.26 | 101.16 | |||||
Return on Common Equity | 76.35 | 63.63 | 48.93 | 84.84 | 101.16 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 75.38 | 76.77 | 79.25 | 81.31 | 83.04 | |||||
SG&A Margin | 21.69 | 21.26 | 20.34 | 18.05 | 17.02 | |||||
EBITDA Margin % | 34.34 | 35.65 | 36.09 | 42.78 | 48.62 | |||||
EBITA Margin % | 31.1 | 32.35 | 33.09 | 40.08 | 46.31 | |||||
EBIT Margin % | 28.88 | 30.32 | 31.61 | 38.86 | 45.56 | |||||
Income From Continuing Operations Margin % | 19.71 | 21.88 | 15.36 | 23.51 | 31.67 | |||||
Net Income Margin % | 19.71 | 21.88 | 15.36 | 23.51 | 31.67 | |||||
Net Avail. For Common Margin % | 19.71 | 21.88 | 15.36 | 23.51 | 31.67 | |||||
Normalized Net Income Margin | 16.71 | 18.33 | 19.13 | 23.41 | 27.93 | |||||
Levered Free Cash Flow Margin | 18.16 | 19.23 | 0.69 | 2.93 | 2.99 | |||||
Unlevered Free Cash Flow Margin | 18.91 | 19.96 | 1.58 | 4.01 | 2.99 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.59 | 0.58 | 0.6 | 0.63 | 0.68 | |||||
Fixed Assets Turnover | 3.21 | 2.98 | 2.96 | 2.81 | 2.96 | |||||
Receivables Turnover (Average Receivables) | 4.51 | 4.21 | 4.27 | 4.48 | 4.53 | |||||
Inventory Turnover (Average Inventory) | 1.77 | 1.62 | 1.4 | 1.26 | 1.04 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.23 | 1.05 | 0.94 | 1.15 | 1.58 | |||||
Quick Ratio | 0.8 | 0.63 | 0.52 | 0.58 | 0.78 | |||||
Operating Cash Flow to Current Liabilities | 0.48 | 0.41 | 0.16 | 0.31 | 0.48 | |||||
Days Sales Outstanding (Average Receivables) | 80.87 | 86.76 | 85.5 | 81.65 | 80.54 | |||||
Days Outstanding Inventory (Average Inventory) | 205.88 | 225.6 | 259.81 | 290.47 | 352.27 | |||||
Average Days Payable Outstanding | 86.95 | 93.18 | 96.73 | 104.2 | 91.3 | |||||
Cash Conversion Cycle (Average Days) | 199.79 | 219.19 | 248.58 | 267.92 | 341.52 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 192.38 | 159.06 | 243.63 | 244.62 | 165.31 | |||||
Total Debt / Total Capital | 65.8 | 61.4 | 70.9 | 70.98 | 62.31 | |||||
LT Debt/Equity | 173.94 | 143.34 | 177.98 | 207.52 | 158.31 | |||||
Long-Term Debt / Total Capital | 59.49 | 55.33 | 51.79 | 60.22 | 59.67 | |||||
Total Liabilities / Total Assets | 81.24 | 78.23 | 83.03 | 81.87 | 76.41 | |||||
EBIT / Interest Expense | 24.07 | 26.1 | 22.2 | 22.42 | - | |||||
EBITDA / Interest Expense | 29.09 | 31.14 | 25.7 | 24.95 | - | |||||
(EBITDA - Capex) / Interest Expense | 25.23 | 25.54 | 18.6 | 18.47 | - | |||||
Total Debt / EBITDA | 1.78 | 1.66 | 2.12 | 1.79 | 1.37 | |||||
Net Debt / EBITDA | 1.26 | 1.36 | 1.82 | 1.59 | 1.14 | |||||
Total Debt / (EBITDA - Capex) | 2.05 | 2.02 | 2.93 | 2.42 | 1.82 | |||||
Net Debt / (EBITDA - Capex) | 1.45 | 1.65 | 2.51 | 2.15 | 1.51 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 15.4 | 0.79 | 19.56 | 32 | 44.7 | |||||
Gross Profit, 1 Yr. Growth % | 12.01 | 2.65 | 23.41 | 35.44 | 47.79 | |||||
EBITDA, 1 Yr. Growth % | 15.43 | 3.62 | 21.02 | 56.47 | 68.52 | |||||
EBITA, 1 Yr. Growth % | 16.96 | 3.72 | 22.31 | 59.88 | 71.57 | |||||
EBIT, 1 Yr. Growth % | 15.15 | 4.6 | 24.66 | 62.24 | 74.27 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -9.88 | 11.88 | -16.08 | 102.08 | 94.9 | |||||
Net Income, 1 Yr. Growth % | -9.88 | 11.88 | -16.08 | 102.08 | 94.9 | |||||
Normalized Net Income, 1 Yr. Growth % | 15.11 | 4.5 | 24.76 | 61.56 | 73.15 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -9.87 | 12.74 | -15.94 | 101.9 | 95.99 | |||||
Accounts Receivable, 1 Yr. Growth % | 13.57 | 3.34 | 31.82 | 21.07 | 61.37 | |||||
Inventory, 1 Yr. Growth % | -2.37 | 10.9 | 33.95 | 31.46 | 81.1 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 3.49 | 12.9 | 27.3 | 30.24 | 42.88 | |||||
Total Assets, 1 Yr. Growth % | 4.66 | 1.4 | 29.33 | 22.98 | 42.89 | |||||
Tangible Book Value, 1 Yr. Growth % | -53.28 | -75.82 | 70.59 | -309.93 | 504.28 | |||||
Common Equity, 1 Yr. Growth % | 59.16 | 18.61 | 1.15 | 31.75 | 85.92 | |||||
Cash From Operations, 1 Yr. Growth % | 11.71 | -2.43 | -44.1 | 107.96 | 90.67 | |||||
Capital Expenditures, 1 Yr. Growth % | -5.63 | 41.57 | 85.92 | 46.7 | 55.02 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 49.8 | 2.6 | -95.51 | 375.58 | 44 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 46.4 | 2.4 | -90.14 | 211.04 | 44 | |||||
Dividend Per Share, 1 Yr. Growth % | 14.86 | 15.29 | 15.31 | 15.04 | 15.38 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 12.64 | 7.85 | 9.77 | 25.62 | 38.2 | |||||
Gross Profit, 2 Yr. CAGR % | 10.13 | 7.23 | 12.56 | 29.28 | 41.48 | |||||
EBITDA, 2 Yr. CAGR % | 15.96 | 9.19 | 11.98 | 37.61 | 63.53 | |||||
EBITA, 2 Yr. CAGR % | 18.94 | 9.94 | 12.63 | 39.84 | 66.94 | |||||
EBIT, 2 Yr. CAGR % | 16.75 | 9.55 | 14.19 | 42.22 | 69.59 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 9.7 | 0.41 | -3.11 | 30.22 | 98.47 | |||||
Net Income, 2 Yr. CAGR % | -18.08 | 0.41 | -3.11 | 30.22 | 98.47 | |||||
Normalized Net Income, 2 Yr. CAGR % | 16.06 | 11.87 | 14.18 | 41.97 | 67.17 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 11.08 | 0.81 | -2.65 | 30.27 | 98.92 | |||||
Accounts Receivable, 2 Yr. CAGR % | 21.14 | 8.34 | 16.72 | 26.33 | 39.77 | |||||
Inventory, 2 Yr. CAGR % | 10.36 | 4.06 | 21.88 | 32.7 | 54.3 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.83 | 8.09 | 19.88 | 33.77 | 36.41 | |||||
Total Assets, 2 Yr. CAGR % | 11.46 | 3.02 | 14.52 | 26.12 | 32.56 | |||||
Tangible Book Value, 2 Yr. CAGR % | -41.8 | -66.39 | -35.78 | 89.24 | 262.47 | |||||
Common Equity, 2 Yr. CAGR % | 85.59 | 37.39 | 9.53 | 15.44 | 56.95 | |||||
Cash From Operations, 2 Yr. CAGR % | 22.52 | 4.4 | -24.13 | 7.82 | 99.13 | |||||
Capital Expenditures, 2 Yr. CAGR % | 12.55 | 15.59 | 62.24 | 65.15 | 50.8 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 1.5 | 25.21 | -79.17 | -49.98 | 158.34 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 1.07 | 23.65 | -69.13 | -42.58 | 158.34 | |||||
Dividend Per Share, 2 Yr. CAGR % | 14.8 | 15.08 | 15.3 | 15.18 | 15.21 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 9.63 | 8.54 | 11.62 | 16.73 | 31.69 | |||||
Gross Profit, 3 Yr. CAGR % | 8.28 | 7.58 | 12.37 | 19.72 | 35.18 | |||||
EBITDA, 3 Yr. CAGR % | 8.4 | 12.06 | 13 | 25.19 | 46.04 | |||||
EBITA, 3 Yr. CAGR % | 11.3 | 14.04 | 13.92 | 26.58 | 48.42 | |||||
EBIT, 3 Yr. CAGR % | 10.71 | 12.99 | 14.37 | 28.37 | 50.84 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 21 | 10.42 | -5.42 | 23.8 | 48.96 | |||||
Net Income, 3 Yr. CAGR % | 19.98 | -9.11 | -5.42 | 23.8 | 48.96 | |||||
Normalized Net Income, 3 Yr. CAGR % | 8.49 | 14.18 | 16.01 | 28.19 | 51.53 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 26.13 | 11.63 | -5.12 | 24.15 | 49.27 | |||||
Accounts Receivable, 3 Yr. CAGR % | 13.25 | 14.89 | 15.66 | 18.15 | 37.07 | |||||
Inventory, 3 Yr. CAGR % | 7.85 | 10.54 | 13.19 | 25 | 47.19 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 3.96 | 8.82 | 14.15 | 26.42 | 36.74 | |||||
Total Assets, 3 Yr. CAGR % | 3.59 | 8 | 11.13 | 17.27 | 31.48 | |||||
Tangible Book Value, 3 Yr. CAGR % | -29.38 | -56.57 | -42.24 | -4.68 | 181.95 | |||||
Common Equity, 3 Yr. CAGR % | -2.97 | 59.86 | 24.06 | 16.48 | 35.57 | |||||
Cash From Operations, 3 Yr. CAGR % | 9.54 | 13.57 | -13.27 | 6.18 | 30.38 | |||||
Capital Expenditures, 3 Yr. CAGR % | 2.66 | 21.5 | 35.43 | 56.89 | 61.71 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 112.05 | 3.22 | -59.25 | -37.71 | -28.22 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 97.9 | 2.81 | -47.45 | -31.69 | -29.14 | |||||
Dividend Per Share, 3 Yr. CAGR % | 14.75 | 14.96 | 15.15 | 15.21 | 15.24 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 5.94 | 7.4 | 9.69 | 15.08 | 21.58 | |||||
Gross Profit, 5 Yr. CAGR % | 6.59 | 7.13 | 9.97 | 15.79 | 23.22 | |||||
EBITDA, 5 Yr. CAGR % | 13.03 | 10.19 | 10.03 | 21.65 | 30 | |||||
EBITA, 5 Yr. CAGR % | 14.1 | 12.35 | 12.07 | 23.73 | 31.63 | |||||
EBIT, 5 Yr. CAGR % | 16.13 | 13 | 12.35 | 23.88 | 32.72 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 15.31 | 135.4 | 10.71 | 17.95 | 27.22 | |||||
Net Income, 5 Yr. CAGR % | 15.31 | 98.21 | 10.15 | 4.95 | 27.22 | |||||
Normalized Net Income, 5 Yr. CAGR % | 13.61 | 12.82 | 11.98 | 24.58 | 34.21 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 18.86 | 142.59 | 13.72 | 18.74 | 27.58 | |||||
Accounts Receivable, 5 Yr. CAGR % | 10.61 | 8.69 | 14.63 | 19.34 | 24.76 | |||||
Inventory, 5 Yr. CAGR % | 1.76 | -0.68 | 13.26 | 18.92 | 28.13 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 1.72 | 2.82 | 10.06 | 18.18 | 24.47 | |||||
Total Assets, 5 Yr. CAGR % | 4.69 | 1.93 | 7.83 | 14.91 | 19.25 | |||||
Tangible Book Value, 5 Yr. CAGR % | -14.43 | -27.72 | -32.01 | -21.75 | 20.42 | |||||
Common Equity, 5 Yr. CAGR % | -8.51 | -1.68 | 1.85 | 40.34 | 36.3 | |||||
Cash From Operations, 5 Yr. CAGR % | 8.4 | 4.76 | -5.15 | 12.76 | 20.93 | |||||
Capital Expenditures, 5 Yr. CAGR % | 4.78 | 11.48 | 23.28 | 37.37 | 41.38 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 12.52 | 20.96 | -15.17 | -23.36 | -11.04 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 12.54 | 20.31 | -4.79 | -19.18 | -12.14 | |||||
Dividend Per Share, 5 Yr. CAGR % | 10.76 | 13.51 | 14.97 | 15.05 | 15.18 |
- Stock Market
- Equities
- LLY Stock
- Financials Eli Lilly and Company
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















